Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICOSLG | O75144 | 10/20 | 0.54 |
| ▸ | ICOS | Q9Y6W8 | 10/20 | 0.54 |
| ▸ | CHUK | O15111 | 12/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619689 | 0.92 | ICOSLG (0.57) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619624 | 0.92 | ICOSLG (0.56) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619639 | 0.92 | ICOSLG (0.56) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL1800310 | 0.91 | ICOSLG (0.60) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619545 | 0.91 | ICOSLG (0.52) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619566 | 0.91 | ICOSLG (0.52) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619653 | 0.91 | ICOSLG (0.52) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL1798960 | 0.91 | ICOSLG (0.61) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619613 | 0.89 | ICOSLG (0.58) | ICOSLGICOSCHUKKMT2AMEN1 | |
| SCHEMBL12619569 | 0.89 | ICOSLG (0.57) | ICOSLGICOSCHUKKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951801-B2 | For therapy of inflammatory disease and cancer | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2206713-A1 | Beta-carbolines useful for treating inflammatory disease | Millennium Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |